GMED Stock Analysis — Globus Medical
Sector: Healthcare
AI Verdict
GMED is cheap for the growth you're getting at 14.9x forward earnings, but the market is demanding proof that its robotics-driven moat will deliver on the aggressive 25.7% EPS growth forecast.
Competitive Moat
Globus Medical specializes in spinal implant devices and robotic-assisted surgery systems, giving it a defensible position through proprietary surgical robotics and surgeon training programs. Its differentiated product ecosystem creates switching costs for hospitals and surgeons who integrate its technology into their practices.
Summary
GMED is notable for its rapid EPS growth expectations paired with a falling forward P/E, suggesting the market is betting on its surgical robotics moat.
Where It Stands
GMED trades at 14.9x next year's earnings versus a healthcare sector median of 22x, while analysts expect 25.7% EPS growth and the trailing P/E is 18.7x.
Key Metrics
- Trailing P/E: 18.7x
- Forward P/E: 14.9x
- PEG Ratio: 0.73
- Earnings Growth: +0.3%
- Revenue Growth: +0.2%
- 52-Week High: $101.40
- 52-Week Low: $54.15
Analyst Consensus
16 Buy · 7 Hold · 0 Sell (23 analysts)
Bull Case
With forward EPS growth at 25.7% and a forward P/E of just 14.9x, you're getting high growth at a cheaper multiple than most healthcare peers.
Bear Case
If the forward P/E reverts to the sector median of 22x without the growth materializing, the stock could see a sharp de-rating despite its 0.73 PEG ratio.
Catalyst to Watch
Watch for surgical robotics adoption rates and new product launches, as any slowdown could challenge the 25.7% EPS growth expectation.